Adjuvants: tailoring humoral immune responses

Area of Science:

• Immunology
• Vaccinology
• Infectious Diseases

Background:

• Current HIV vaccine development seeks to surpass the 31% efficacy of the RV144 trial.
• Inducing broadly reactive HIV neutralizing antibodies is a key goal.
• Advances in immunogen design and adjuvant formulations are progressing concurrently.

Purpose of the Study:

• To review the development of novel adjuvants beyond traditional aluminum and emulsion formulations.
• To explore the mechanistic role of adjuvants in stimulating innate immunity.
• To identify opportunities for improving candidate vaccine designs against HIV-1 acquisition.

Main Methods:

• Review of preclinical and early phase 1 clinical trial data.
• Focus on rational pairing of vaccine concepts with advanced adjuvant formulations.
• Emphasis on formulation science, delivery methods, and targeted safety/immune evaluations.

Main Results:

• New adjuvants with immune-potentiating properties are being evaluated.
• These adjuvants are tested with HIV Env-containing immunogens in prime-boost and subunit regimens.
• Early clinical evaluations are underway for these novel combinations.

Conclusions:

• Optimizing adjuvanted vaccine formulations is crucial for developing a potent and long-lived HIV vaccine.
• Continued research into formulation science, delivery, and evaluation is necessary.
• New adjuvants hold promise for enhancing vaccine efficacy against HIV-1.